Engaging College Students in Developing and Testing a Video-based Intervention for HPV Vaccination Promotion

NCT ID: NCT06397378

Last Updated: 2025-09-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

123 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-08-16

Study Completion Date

2026-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

HPV vaccines offer hope against HPV-associated cancers for males and females; however, the rate of vaccination has not reached projected public health goals. This study will engage key stakeholders in the research process to co-design and pilot testing a video-based intervention addressing low HPV vaccination rates among college students The intervention and its approach have the potential to reduce health disparities in HPV-associated cancers in young adults via low-cost technology and timely intervention.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Human papillomavirus (HPV) infection is the most common sexually transmitted infection in the United States (U.S.) and a significant public health issue, as almost all sexually active individuals contract it at some point in their lives. Approximately 79 million Americans are infected with HPV, most in their late teens or early 20s. HPV has been found to be associated with cancers for females (e.g., cervical cancer) and males (e.g., penile cancer). The high morbidity, mortality, and economic burden attributed to cancer-causing HPV call for researchers to address this public health concern through vigorous prevention efforts, including HPV vaccination.

HPV-associated cancers could be prevented through vaccination. HPV vaccination is recommended for individuals aged 9-26 years. Economic models have shown that HPV vaccination of adolescents and young adults is cost effective; however, HPV vaccination rates are falling dramatically short of the 80% Healthy People 2030 target recommendation. Young adults such as college students are at higher risk for HPV infection but a significant portion of them is not yet vaccinated against HPV.

Empirical evidence suggests that a lack of awareness and knowledge about HPV and the vaccine, the inconvenience of getting the vaccine, and concern about side effects are main barriers for college students. Current interventions developed to increase HPV vaccination rates are primarily focusing on adolescents as recipients. In the limited interventions developed to address low HPV vaccination rates among college students, most of them only included female college students. In one online RCT study that young adults aged 18-26 were randomized into intervention group (YouTube videos) reported significantly higher vaccination intention compared to comparison group (educational pamphlet); however, the vaccination status was not assessed. College students have advocated for educational videos featuring healthcare providers and peers and sharing videos on YouTube and Instagram.

To our knowledge, this study is the first one of a few video-based interventions co-designed with the main stakeholder-college students to address the low HPV vaccination rates in this at-risk population. This novel intervention is brief, portable, tailored to college students and feasible to fit the intervention into college student\'s busy schedules.

The investigators will develop a video-based intervention and conduct a pilot randomized trial comparing this intervention to an HPV Fact Sheet developed by CDC. The investigators will target college students aged 18-26 because of their higher risk of contracting HPV infection and low vaccination rates. Aim 1. Develop a developmentally and culturally congruent video-based intervention for college students aged 18-26. The investigators will recruit and form a student advisory board (SAB) consisting of 8-10 college students aged 18-26 to assist with developing four brief HPV education videos (each 2-3 mins long; two will be revised from Co-I's prior research). The advisory board will provide input on the study recruitment plan, assessments, and be involved in data interpretation and dissemination processes. Aim 2. Conduct a pilot randomized controlled trial (RCT) to examine the feasibility (participation rate, retention, intervention fidelity), acceptability (satisfaction) and preliminary efficacy of the intervention to promote HPV vaccination among 80 college students aged 18-26.

Once consented, participants will receive assessments at baseline (T0) using the web-based data collection tool, Qualtrics, before being assigned to one of the two study arms. Participants will be invited to fill out Time 1 (T1) assessment immediately after the intervention (video vs. Fact Sheet) and Time 2 (T2) assessment 2 months after completion of the intervention. The interventions (video and CDC Fact Sheet) and T0-T2 assessments will be administered online. A resource kit including available resources to obtain vaccines will be provided to all participants after T2 assessment. The investigators will also provide the video-based intervention to the students in the comparison arm after T2 assessment should they be interested. Videos will be sent out after participants complete T0. One video will be sent out every 3 days and the intervention (4 videos in total) will be completed in 2-week via emails. Participants in the intervention group can watch the videos at their leisure.

Feasibility will be assessed by response rate (percentage of eligible individuals agreeing to participate), retention (proportion retained through follow-up and complete T0-T2 assessments), intervention fidelity (% of participants watch all stories). Acceptability will be assessed via two Likert-type satisfaction questions. Based on our prior research, the investigators will use the following benchmarks to determine study feasibility as ≥ 80% response rate, ≥ 80% retention rate, ≥ 80% intervention fidelity, and acceptability by a mean satisfaction score ≥ 4.0. Preliminary efficacy will be determined by the % of participants completing the 1st HPV vaccine does within 2 months of completing the intervention.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

N/A - Healthy Subjects

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

This study has been approved by the host university's Biomedical and Health Institutional Review Board (Study ID: STUDY00010264). We propose conducting a two-phase, mixed-methods research project to co-develop a culturally and developmentally appropriate video-intervention (Phase 1) with a Student Advisory Board (SAB) composed of eight college students with diverse background (sex, age, discipline). Once the videos are finalized, we will engage the SAB in the Phase 2 activities aimed to examine the feasibility, acceptability, and preliminary effectiveness of a RCT among college students aged 18-26.
Primary Study Purpose

OTHER

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group using CDC factsheet

We did not develop this intervention. Instead, we will use information from the CDC website on HPV and the HPV vaccine and convert it into a narrated voiceover video to ensure the information is delivered in the same format as our video-based intervention.

Group Type ACTIVE_COMPARATOR

CDC HPV Fact Sheet

Intervention Type OTHER

We did not develop this intervention. Instead, we will use information from the CDC website on HPV and the HPV vaccine and convert it into a video with a narrated voiceover format.

Because our student advisory board will develop four short videos, participants who are randomly assigned to the CDC fact sheet group will watch the converted CDC video four times to ensure that all groups are exposed to the same number of videos.

Here is the CDC link: https://www.cdc.gov/hpv/vaccines/?CDC\_AAref\_Val=https://www.cdc.gov/hpv/parents/vaccinesafety.html

Group using videos

Ninety-three college students will be randomly assigned to three groups (31 participants in each video group Vs. 30 participants in the CDC group) to watch the created videos. The videos will be presented in randomized order and distributed to participants to minimize bias.

Group Type EXPERIMENTAL

short videos related to HPV and the HPV vaccine

Intervention Type OTHER

Eight college students created and developed four videos on human papillomavirus (HPV) and the HPV vaccine, designed to increase their knowledge and attitude, shape subjective norms, enhance perceived behavioral control, and strengthen intentions to receive the HPV vaccine. Two months after the video intervention, we will follow up with participants to collect their self-reported vaccine uptake status.

Outcomes will be compared with those of another group whose participants will watch a video presenting CDC information on HPV and the HPV vaccine, adapted into a narrated voiceover format.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

short videos related to HPV and the HPV vaccine

Eight college students created and developed four videos on human papillomavirus (HPV) and the HPV vaccine, designed to increase their knowledge and attitude, shape subjective norms, enhance perceived behavioral control, and strengthen intentions to receive the HPV vaccine. Two months after the video intervention, we will follow up with participants to collect their self-reported vaccine uptake status.

Outcomes will be compared with those of another group whose participants will watch a video presenting CDC information on HPV and the HPV vaccine, adapted into a narrated voiceover format.

Intervention Type OTHER

CDC HPV Fact Sheet

We did not develop this intervention. Instead, we will use information from the CDC website on HPV and the HPV vaccine and convert it into a video with a narrated voiceover format.

Because our student advisory board will develop four short videos, participants who are randomly assigned to the CDC fact sheet group will watch the converted CDC video four times to ensure that all groups are exposed to the same number of videos.

Here is the CDC link: https://www.cdc.gov/hpv/vaccines/?CDC\_AAref\_Val=https://www.cdc.gov/hpv/parents/vaccinesafety.html

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Inclusion Criteria: college students aged 18-26 never receive HPV vaccines able to understand English.

Exclusion Criteria: not able to understand English younger than 18 or older than 26 years old have received HPV vaccines.
Minimum Eligible Age

18 Years

Maximum Eligible Age

26 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Michigan State University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

ChengChing Hiya Liu

Associate Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Michigan State University

East Lansing, Michigan, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

ChengChing Hiya Liu, Ph. D.

Role: CONTACT

626-566-4835

Angela Chia-Chen Chen, Ph.D.

Role: CONTACT

5173534747

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Cheng-Ching Hiya Liu, Ph.D.

Role: primary

626-566-4835

Cheng-Ching Liu, Ph.D.

Role: backup

626-566-4835

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PD66847

Identifier Type: OTHER

Identifier Source: secondary_id

MSUSTUDY10264

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Promoting HPV Vaccination Among Young Adults in Texas
NCT05057312 ACTIVE_NOT_RECRUITING NA
Stories to Prevent (StoP) HPV Cancers
NCT06808776 RECRUITING NA